These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 16122884)
1. Metallothionein expression in invasive and in situ breast carcinomas. Gallicchio LM; Flaws JA; Fowler BA; Ioffe OB Cancer Detect Prev; 2005; 29(4):332-7. PubMed ID: 16122884 [TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation. Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161 [TBL] [Abstract][Full Text] [Related]
3. Breast carcinoma in women 35 years and younger: a pathological study. Fernandopulle SM; Cher-Siangang P; Tan PH Pathology; 2006 Jun; 38(3):219-22. PubMed ID: 16753742 [TBL] [Abstract][Full Text] [Related]
4. Expression of metallothionein in invasive ductal breast cancer in relation to prognosis. Zhang R; Zhang H; Wei H; Luo X J Environ Pathol Toxicol Oncol; 2000; 19(1-2):95-7. PubMed ID: 10905514 [TBL] [Abstract][Full Text] [Related]
5. Over-expression of metallothionein predicts chemoresistance in breast cancer. Yap X; Tan HY; Huang J; Lai Y; Yip GW; Tan PH; Bay BH J Pathol; 2009 Mar; 217(4):563-70. PubMed ID: 19116991 [TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical study of matrix metalloproteinases and their inhibitors in pure and mixed invasive and in situ ductal carcinomas of the breast. Gonzalez LO; Junquera S; del Casar JM; González L; Marín L; González-Reyes S; Andicoechea A; González-Fernández R; González JM; Pérez-Fernández R; Vizoso FJ Hum Pathol; 2010 Jul; 41(7):980-9. PubMed ID: 20236691 [TBL] [Abstract][Full Text] [Related]
7. Molecular evidence for progression of microglandular adenosis (MGA) to invasive carcinoma. Shin SJ; Simpson PT; Da Silva L; Jayanthan J; Reid L; Lakhani SR; Rosen PP Am J Surg Pathol; 2009 Apr; 33(4):496-504. PubMed ID: 19047897 [TBL] [Abstract][Full Text] [Related]
8. Are encapsulated papillary carcinomas of the breast in situ or invasive? A basement membrane study of 27 cases. Esposito NN; Dabbs DJ; Bhargava R Am J Clin Pathol; 2009 Feb; 131(2):228-42. PubMed ID: 19141383 [TBL] [Abstract][Full Text] [Related]
9. Mean nuclear area and metallothionein expression in ductal breast tumors: correlation with estrogen receptor status. El Sharkawy SL; Farrag AR Appl Immunohistochem Mol Morphol; 2008 Mar; 16(2):108-12. PubMed ID: 18227734 [TBL] [Abstract][Full Text] [Related]
10. Cigarette smoking and metallothionein expression in invasive breast carcinomas. Gallicchio L; Flaws JA; Sexton M; Ioffe OB Toxicol Lett; 2004 Sep; 152(3):245-53. PubMed ID: 15331133 [TBL] [Abstract][Full Text] [Related]
11. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238 [TBL] [Abstract][Full Text] [Related]
12. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525 [TBL] [Abstract][Full Text] [Related]
13. Β-catenin expression in in situ and infiltrative ductal carcinomas of the breast. Karabacak T; Eğılmez R; Arpaci RB; Pfeiffer ES Turk Patoloji Derg; 2011; 27(3):185-8. PubMed ID: 21935866 [TBL] [Abstract][Full Text] [Related]
14. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Steinman S; Wang J; Bourne P; Yang Q; Tang P Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367 [TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical detection of antiapoptotic protein X-linked inhibitor of apoptosis in mammary carcinoma. Jaffer S; Orta L; Sunkara S; Sabo E; Burstein DE Hum Pathol; 2007 Jun; 38(6):864-70. PubMed ID: 17350670 [TBL] [Abstract][Full Text] [Related]
16. Expression of E-cadherin in human ductal breast cancer carcinoma in situ, invasive carcinomas, their lymph node metastases, their distant metastases, carcinomas with recurrence and in recurrence. Jeschke U; Mylonas I; Kuhn C; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K Anticancer Res; 2007; 27(4A):1969-74. PubMed ID: 17649807 [TBL] [Abstract][Full Text] [Related]
17. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma. Sanlioglu AD; Korcum AF; Pestereli E; Erdogan G; Karaveli S; Savas B; Griffith TS; Sanlioglu S Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):716-23. PubMed ID: 17512128 [TBL] [Abstract][Full Text] [Related]
18. Lack of relationship between metallothionein (MT) expression and proliferation exponents in cells of primary ductal breast cancer of G2 grade of differentiation. Surowiak P; Paluchowski P; Dziegiel P; Wysocka T; Wojnar A; Spaczyński M; Zabel M Med Sci Monit; 2004 Aug; 10(8):BR300-5. PubMed ID: 15277992 [TBL] [Abstract][Full Text] [Related]
19. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast. Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076 [TBL] [Abstract][Full Text] [Related]
20. Does thymidine phosphorylase correlate with angiogenesis in intraductal carcinoma of the breast? Erkus M; Meteoglu I; Culhaci N; Meydan N; Erdogdu I Saudi Med J; 2006 Sep; 27(9):1329-33. PubMed ID: 16951768 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]